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Abstract
Background: In conjunction with posttranslational chromatin modifications, proper arrangement of higher order
chromatin structure appears to be important for controlling transcription in the nucleus. Recent genome-wide
studies have shown that the Estrogen Receptor-alpha (ERα), encoded by the ESR1 gene, nucleates tissue-specific
long-range chromosomal interactions in collaboration with the cohesin complex. Furthermore, the Mediator
complex not only regulates ERα activity, but also interacts with the cohesin complex to facilitate long-range
chromosomal interactions. However, whether the cohesin and Mediator complexes function together to contribute
to estrogen-regulated gene transcription remains unknown.
Results: In this study we show that depletion of the cohesin subunit SMC3 or the Mediator subunit MED12
significantly impairs the ERα-regulated transcriptome. Surprisingly, SMC3 depletion appears to elicit this effect
indirectly by rapidly decreasing ESR1 transcription and ERα protein levels. Moreover, we provide evidence that both
SMC3 and MED12 colocalize on the ESR1 gene and are mutually required for their own occupancy as well as for
RNAPII occupancy across the ESR1 gene. Finally, we show that extended proteasome inhibition decreases the
mRNA expression of cohesin subunits which accompanies a decrease in ESR1 mRNA and ERα protein levels as well
as estrogen-regulated transcription.
Conclusions: These results identify the ESR1 gene as a cohesin/Mediator-dependent gene and indicate that this
regulation may potentially be exploited for the treatment of estrogen-dependent breast cancer.
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Background
Transcriptional control is a highly ordered and complex
process involving interactions between various transcrip-
tion factors and the transcriptional apparatus [1]. Im-
portantly, changes in chromatin organization, including
post-translational histone modifications and higher order
chromatin structure direct transcriptional activity and
control gene expression patterns [2,3]. Recent studies
have begun to uncover the complexity of interactions
between different chromatin loci on a genome-wide level
[4-6].
The estrogen receptor-alpha (ERα) is a ligand-activated
transcription factor which plays an essential role in direct-
ing tissue-specific gene expression [7]. Importantly, ERα is
a primary target for anti-estrogen therapy in breast cancer
and its presence is a prognostic marker for patient out-
come [7,8]. Interfering with distinct aspects of ERα-regu-
lated transcription may provide novel therapeutic options
for the treatment of ERα-positive breast cancer [9]. During
gene transcription ERα functions not only to recruit an in-
tricate network of transcriptional coregulators, but also
nucleates long-range chromosomal interactions [4]. These
functions are important for directing cell type-specific
transcriptional programs [10].
Long-range chromosomal interactions appear to be sta-
bilized by the cohesin complex [11]. In mammals, the
cohesin complex consists of a ring structure containing
SMC1A and SMC3 which is held together by the proteins
RAD21 and STAG1/STAG2. Cohesin plays a central role
in sister chromatid cohesion during and following DNA
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replication [11]. Consistently, mutations in the cohesin
complex have been found in different types of cancer and
have been linked to aneuploidy [12,13]. Interestingly, muta-
tions in the Nipped-B-like (NIPBL) gene [14-16], which
loads the cohesin complex onto chromatin, or mutations
in SMC1A or SMC3 [17-19] lead to a developmental
phenotype called Cornelia de Lange Syndrome (CdLS). In
addition to developmental phenotypes such as delayed
neurodevelopment and other structural abnormalities,
CdLS patients frequently exhibit potential endocrine-
related defects such as slower pubertal growth and irregu-
lar menstrual cycles [20]. Consistent with a potential
particular importance of cohesin in endocrine-regulated
processes, cohesin subunits have been implicated in tran-
scriptional regulation by some nuclear hormone receptors
in both mammalian cells and in Drosophila [4,10,21-24].
Furthermore, a number of studies indicate that the pheno-
types observed in CdLS patients are likely not due to
defects in sister chromatid cohesion, but rather to changes
in transcription [25,26].
Mediator is a large multisubunit complex which inter-
acts directly with a number of transcription factors to fa-
cilitate RNA Polymerase II (RNAPII) recruitment to
target genes [27]. Recent studies indicated that Mediator
also interacts with cohesin to control long-range chromo-
somal interactions in embryonic stem cells [28]. Given the
important role of Mediator in controlling ERα function
[29-31] and the potential importance of cohesin in con-
trolling ERα-nucleated long-range chromosomal interac-
tions [4,10], we hypothesized that these complexes may
similarly control estrogen-regulated gene expression. Our
results show that depletion of components of either the
cohesin or Mediator complexes significantly impairs ERα-
regulated gene transcription. Surprisingly, this effect
appears to be due to decreased transcription of the ESR1
gene following SMC3 knockdown. These effects could be
mimicked by prolonged treatment with the clinically
utilized proteasome inhibitor bortezomib which also
decreased the mRNA levels of ESR1 and several cohesin
subunits as well as SMC3 and ERα protein levels. These
results provide an important molecular insight into the
possible clinical benefit of proteasome inhibitor treatment
for estrogen-dependent breast cancer and may also ex-
plain potential endocrine phenotypes frequently observed
in patients with CdLS.
Results
SMC3 and MED12 knockdown decrease ERα-dependent
transcription
In order to determine whether cohesin and Mediator
are both required for estrogen-regulated transcription,
we performed siRNA-mediated knockdown studies of
both SMC3 and MED12 in MCF7 breast cancer cells.
We investigated the expression of the CXCL12, GREB1,
PGR and PKIB genes which we previously identified as
robust estrogen-regulated genes in transcriptome-wide
studies [32] and which all demonstrate occupancy of
cohesin components and ER/cohesin-based chromo-
somal looping [4,10,32]. As shown in Figure 1A (and
Figure 1A in Additional file 1), depletion of SMC3,
MED12 or RAD21 significantly decreased the estrogen-
induced mRNA levels of each of the estrogen-regulated
genes tested. Notably, SMC3 knockdown also decreased
the basal expression of these estrogen-regulated genes
even in the absence of estrogen. These effects are rem-
iniscent of those observed upon treatment with the pure
anti-estrogen ICI 182,780, where both estrogen-induced
and basal expression of estrogen responsive genes is
affected by anti-estrogen treatment [33]. Thus, both
basal and estrogen-induced expression of estrogen tar-
get genes appears to be dependent upon cohesin and
Mediator for its activity. In contrast, SMC3 and MED12
mRNA expression was unaffected by either estrogen
treatment or knockdown of the other component
(Figure 1B).
To further examine the extent of the effects of SMC3
and MED12 knockdown on ERα activity, we performed
transcriptome-wide analyses comparing the effects of
each individual knockdown on the transcriptional pro-
file of MCF7 cells both in the presence and absence of
estrogen. As shown in Figure 2A, SMC3 depletion
significantly blocked the overwhelming majority of es-
trogen-regulated gene transcription in MCF7 cells
(compare Figure 2A left and right columns). Moreover,
consistent with the single gene studies in Figure 1A,
even the basal levels of expression were significantly
affected (middle column). This effect was not limited to
transcriptional activation since estrogen-repressed gene
transcription was also reversed. A similar, albeit some-
what weaker, effect was also observed for MED12
knockdown (Figure 2B).
Cohesin or mediator knockdown impairs ESR1 gene
expression
Unexpectedly, in the process of bioinformatic analysis
of these transcriptome data, we found ESR1 mRNA
levels were also SMC3-dependent. We therefore per-
formed time course analyses of RNA (Figure 3A) and
protein (Figure 3B) expression to determine the kinet-
ics of SMC3 and ESR1 regulation upon SMC3 deple-
tion. These studies revealed a very rapid and parallel
downregulation of SMC3 and ESR1 RNA levels already
at 12 h after transfection of SMC3 siRNA (Figure 3A).
Similarly, RAD21 knockdown also decreased ESR1
mRNA levels as well (Figure 1B in Additional file 1).
ERα protein levels were also decreased following
knockdown of either SMC3 or MED12 (Figure 3B).
Surprisingly, despite their reported long half-lives, both
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SMC3 and ERα protein levels were similarly decreased
already 12 h post-transfection (Figure 3C). Thus, ESR1
expression is highly dependent upon cohesin and
Mediator.
SMC3 and MED12 are required for mutual occupancy and
transcription across the ESR1 gene
Previous chromatin immunoprecipitation-sequencing
(ChIP-seq) studies revealed cohesin binding sites
Figure 1 SMC3 and MED12 depletion significantly reduces the estrogen-induced expression of ERα target genes. MCF7 cells transfected
with control, SMC3 or MED12 siRNA were grown in normal growth medium for 24 h and then for another 42 h in hormone-depleted medium
before treating with 10 nM 17β-Estradiol (E2) for 6 h as indicated. Total mRNA was extracted, reverse-transcribed and analyzed by quantitative
real-time PCR (qRT-PCR). (A) The expression levels of the estrogen-regulated genes CXCL12, GREB1, PGR, and PKIB were normalized to 28S
ribosomal mRNA, graphed relative to the control sample and expressed as relative mRNA expression; mean values + SD, n = 4. (B) Efficient
knockdown of MED12 and SMC3 was verified by qRT-PCR in the same samples used in (A). MED12 and SMC3 were normalized and expressed as
in (A). Mean values + SD, n = 4.
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genome-wide in both the presence and absence of estro-
gen in MCF7 cells [10]. Analysis of these data revealed a
number of cohesin binding sites on the ESR1 gene
(Figure 4A). We therefore performed ChIP analyses to
verify cohesin binding to the ESR1 gene. As shown in
Figure 4B, SMC3 was present at both of the investigated
cohesin binding sites, but at much lower levels near the
transcriptional start site (TSS) or 30 end of the ESR1
gene. Importantly, SMC3 occupancy was decreased by
either SMC3 or MED12 knockdown.
Consistent with a cooperative function with SMC3,
MED12 was also present at both cohesin binding sites
(Figure 4C). In addition, it was also found in significant
levels at the TSS, but not at the 30 end. This finding is
consistent with the important role of the Mediator com-
plex in transcriptional initiation.
To determine the effects of SMC3 and MED12 deple-
tion on RNAPII-dependent ESR1 transcription, we also
investigated the occupancy of both total and elongating
RNAPII (phosphorylated at Ser2 of the heptapeptide re-
peat in the C-terminal domain). Consistent with the
decreased ESR1 mRNA levels observed in Figure 3A,
total RNAPII levels were decreased at the TSS and 30
end of the ESR1 gene after SMC3 or MED12 siRNA
transfection (Figure 4D). However, significant levels of
RNAPII were still present even after depletion of SMC3
or MED12 depletion. The effects of SMC3 or MED12
were more apparent when investigating the effects on
elongating RNAPII. Surprisingly, while P-Ser2 RNAPII is
generally enriched at higher levels in the transcribed re-
gion and 30 end of active genes, significant levels were
observed at both ends of the ESR1 gene. These results
are similar to that observed for other genes, which
demonstrated similar or higher levels of P-Ser2 RNAPII
at the TSS compared to the transcribed region [34].
Importantly, the levels of P-Ser2 RNAPII were reduced
to background levels at both the TSS and 30 end in the
absence of either SMC3 or MED12 (Figure 4E). Thus,
the knockdown of components of either the cohesin or
Mediator complexes may affect both transcriptional ini-
tiation as well as elongation.
Bortezomib decreases SMC3 and ESR1 gene expression
In a previous study we showed that short-term (2 h)
treatment with the clinically utilized proteasome inhibi-
tor bortezomib had no effect on ERα recruitment to tar-
get gene expression [32]. However, another study
demonstrated that chronic treatment with bortezomib
decreased ESR1 mRNA and ERα protein levels [35].
Therefore, we also tested the effects of bortezomib treat-
ment on estrogen-regulated gene expression in this sys-
tem. Indeed, bortezomib treatment for 6 h significantly
decreased the estrogen-induced mRNA levels of
CXCL12, PGR, GREB1 and PKIB (Figure 5A). These
results paralleled a decrease in estrogen-induced long-
range chromosomal interactions on both the CXCL12
and GREB1 genes (Figure 5B).
To verify the effects of bortezomib treatment on ESR1
expression and to test whether a similar effect could be
observed for cohesin and/or Mediator subunits, we
examined ESR1, MED12 and cohesin subunit mRNA
levels at various time points following bortezomib treat-
ment. As shown in Figure 6A, ESR1 and SMC3 showed
similar profiles with the mRNA levels of both being un-
affected at 2 h and greater effects at 6 and 24 h after
treatment. Similar effects were also observed for STAG1
and RAD21, and to a lesser extent SMC1A, whose
mRNA levels also decreased following extended bortezo-
mib treatment, albeit to differing degrees. In contrast,
Figure 2 SMC3 or MED12 depletion significantly impairs the estrogen-regulated transcriptome. mRNA expression profiling of estrogen-
regulated genes after SMC3 (A) or MED12 (B) depletion and 10 nM 17β-Estradiol (E2) treatment for 6 h. The heatmaps show log2-fold-changes in
experiments control siRNA+ 17β-Estradiol vs. control siRNA alone (E2), SMC3 (A) or MED12 (B) siRNAs vs. control siRNA (siRNA SMC3 or siRNA
MED12) and SMC3 (A) or MED12 (B) siRNAs + 17β-Estradiol vs. control siRNA (siRNA SMC3+ E2 or siRNA MED12+ E2) (columns) for genes that are
significantly (q < 0.05; q = P-values adjusted to False discovery rate regulated by estrogen (Fold-change, FC <−log2 (1.5) or FC > log2 (1.5)) (rows).
The color keys range from red marking downregulated, to blue marking upregulated genes; mean values; n = 3.
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MED12 mRNA levels were only mildly and transiently
affected by bortezomib treatment. The effects on cohesin
and ERα were also substantiated at the protein levels
where bortezomib treatment resulted in decreased
SMC3 and ERα protein levels (Figure 6B). In contrast, as
previously reported [36], estrogen treatment alone also
decreased ERα protein levels without affecting SMC3
levels.
ESR1 and SMC3 regulation is not due to a cell cycle arrest
Given its essential role in cell cycle progression, it was
conceivable that the changes observed in SMC3 (and
consequently also ESR1) gene expression upon bortezo-
mib treatment (or cohesin knockdown) may be due to a
general effect caused by a cell cycle arrest. Interestingly,
while cohesin activity is required for sister chromatin co-
hesion, knockdown of either SMC3 or MED12 and fur-
ther growth under hormone-free conditions resulted in
a slight increase in the G1 fraction of cells compared to
control transfected cells (Figure 2 in Additional file 1).
In order to test whether the gene expression effects we
observed were due to a G1 cell cycle arrest, we induced
a G1 arrest by growing cells under serum-free conditions.
Although this treatment substantially increased the G1
fraction of cells (Figure 7A), serum withdrawal had no
effect on either SMC3 or ESR1 mRNA or protein levels
(Figure 7B and C).
Discussion
Genome organization within the nucleus is emerging as
one of the most exciting, but highly complex gene expres-
sion regulatory mechanisms. The recent development of
new laboratory techniques and the advent of next gener-
ation sequencing technologies have made it possible to
analyze intra- and inter-chromosomal interactions on a
genome-wide level. Despite these advances much still
remains to be learned about the extensive network of pro-
teins controlling genome organization and the plasticity of
its regulation.
In this study we sought to determine the role of the
cohesin and Mediator complexes in controlling estrogen-
dependent gene transcription. While we saw a substantial
reversal in the estrogen-regulated gene expression pattern
following depletion of components of each complex, these
effects may be an indirect effect caused by decreased ESR1
expression. Consistently, both SMC3 and MED12 protein
binding was detected on the ESR1 gene and depletion of
either component not only affected their occupancy, but
also RNAPII occupancy on the ESR1 gene. Thus, these
data imply that a specific Mediator/cohesin-directed
Figure 3 SMC3 knockdown decreases ERα gene expression and protein level. (A) MCF7 cells were transfected with control or SMC3 siRNA.
After cell adhesion, growth medium was changed to hormone-deprived 5% CSS medium. Total mRNA was harvested 12, 24, 36 and 48 h after
transfection. SMC3 and ESR1 expression was normalized to 28S ribosomal mRNA, graphed relative to the control sample and expressed as relative
mRNA expression; mean values + SD, n = 2. (B) MCF7 cells were transfected with control, SMC3 or MED12 siRNAs and grown overnight. Cells were
switched to hormone-free medium for 32 hours before harvesting whole protein extracts and analysis by Western blot for MED12, SMC3, ERα
and HSC70 protein levels. (C) MCF7 cells were transfected as in (A). Whole protein extracts were analyzed via Western blot with specific
antibodies for SMC3 and ERα. β-Actin and HSC70 are shown as loading controls.
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Figure 4 The ESR1 gene is a target of regulation by the cohesin and Mediator complexes. (A) A snapshot from the UCSC genome browser
showing the structure of the ESR1 gene and cohesin binding sites previously identified by chromatin immunoprecipitation-sequencing (ChIP-Seq)
[10]. The indicated positions shown for the investigated cohesin binding sites as well as the transcriptional start site (TSS) and the 30 end. (B-E)
MCF7 cells transfected with control, SMC3 or MED12 siRNAs for 24 h were grown in estrogen-free medium for an additional 48 h. SMC3 (B),
MED12 (C), RNAPII (D) and RNAPII P-Ser2 (E) binding to the transcriptional start site (TSS), two different cohesin binding sites (Coh. A and B), and
the 30 end (A) was analyzed using specific antibodies by chromatin immunoprecipitation analysis. ChIP samples were normalized to input
samples and expressed as % input; mean values + SD, n = 3. The dotted line indicates the background binding as measured by the average signal
of non-specific IgG binding across all samples and sites.
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Figure 5 Proteasome inhibition using bortezomib negatively influences estrogen-induced gene regulation. (A) After pre-treatment with
50 nM bortezomib (Bort) or vehicle (ethanol, Cont) for 15 minutes, MCF7 cells were incubated with 10 nM 17β-Estradiol (E2) for 6 h before
extracting total mRNA. The expression levels of estrogen target genes CXCL12, GREB1, PGR and PKIB were normalized to 28S ribosomal mRNA,
graphed relative to the control sample and expressed as relative mRNA expression; mean values + SD, n = 4. (B) Chromatin conformation capture
(3C) analysis of positive and negative interactions at the CXCL12 and GREB1 loci as identified by Schmidt et al. [10] and previously described [32]
(upper panel). MCF7 cells, pre-treated with 50 nM bortezomib (Bort) or vehicle (ethanol, Cont) for 15 minutes, were incubated with 10 nM 17β-
Estradiol (E2) for 24 h. Purified DNA samples were quantified by qPCR using a standard curve containing the respective BAC clones for CXCL12 or
GREB1. The 3C template values were normalized to values from an internal control site that lies between restriction enzyme sites, graphed relative
to the control sample (set to 1) and represented as normalized relative interaction; mean values + SD, n = 3.
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Figure 6 Bortezomib treatment decreases ERα and cohesin expression. (A) MCF7 cells were treated with vehicle (ethanol, Cont) or 50 nM
bortezomib (Bort) for 2, 6 or 24 h. Total mRNA was harvested and reverse-transcribed. The expression levels of ESR1, SMC3, SMC1A, STAG1, RAD21
and MED12 genes were normalized to 28S ribosomal mRNA and graphed as in (A); mean values + SD, n =2. (B) MCF7 cells were treated with
either vehicle (ethanol, Cont), 10 nM 17β-Estradiol (E2) or 50 nM bortezomib (Bort) for 24 h. SMC3 and ERα protein levels were analyzed by
Western blot analysis. β-Actin is shown as loading control.
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Figure 7 Cell cycle arrest does not affect SMC3 and ERα expression. (A) MCF7 cells were grown under normal growth or serum-free
conditions and analyzed by bromodeoxyuridine (BrdU) and propidium iodide-based flow cytometry. Serum withdrawal induces a clear decrease
in the S phase fraction and increase in the G1 cell fraction. (B) Total RNA from cells as treated in (A) was harvested, reverse-transcribed and gene
expression was measured by qRT-PCR. SMC3 and ESR1 expression were normalized to 28S ribosomal mRNA, graphed relative to the control
sample and expressed as relative mRNA expression; mean values + SD, n = 2. (C) MCF7 cells were grown as in (A) and (B) and SMC3 and ERα
protein levels were analyzed by Western blot analysis. β-Actin is shown as loading control.
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higher order chromatin structure is essential for proper
ESR1 expression. In the course of this study a number of
possible interactions between various cohesin binding sites
on the ESR1 gene were tested by chromatin conformation
capture analyses. Unfortunately, interactions between the
investigated sites could not be observed (data not shown).
This finding is consistent with recent data demonstrating
that many long-range chromosomal interactions do not
necessarily occur between adjacent cohesin binding sites
but rather often encompass chromosomal loops of several
hundred kilobases [4]. Thus it is currently impossible to
precisely predict which cohesin binding sites and which
chromatin interactions are essential for directing proper
ESR1 gene transcription. Additional studies in MCF7 cells
using cohesin components for genome-wide chromo-
somal interaction analyses, similar to those recently
reported for CTCF in embryonic stem cells [5], may help
to uncover these interactions. Furthermore, additional
non-looping functions of cohesin (for example, through
direct interaction with other transcriptional regulatory
proteins) cannot be excluded and must be considered.
Previous studies indicated a critical role for cohesin
components in controlling ERα-regulated gene tran-
scription [4,10]. Although cohesin likely plays a direct
role in ERα-directed transcription, the finding that the
expression of the ESR1 gene itself is directly controlled
by the cohesin complex suggests that caution will also
need to be used when interpreting other siRNA-mediated
knockdown studies of cohesin complex components.
Similar effects were also recently observed when investi-
gating the effects of cohesin on ecdysone receptor-regu-
lated transcription [23,24]. One potential aspect which
may affect the results in many studies is the cell cycle-
dependent effects of cohesin knockdown. Given the im-
portant role of cohesin in sister chromatid cohesion, a
knockdown of cohesin complex components will affect
cell cycle progression. As previously reported [10] and
demonstrated in our results, given the cell cycle arrest
induced by estrogen withdrawal, this aspect likely does
not influence the interpretation of our data. However, the
molecular mechanism leading to the reported defect in es-
trogen-induced S-phase entry following depletion of the
cohesin complex component RAD21 [10] may need to be
reassessed. In this case, the effects observed may not be
due to defects in the induction of ERα-directed chromo-
somal interactions, but rather due to an upstream loss of
ESR1 gene expression. Given the complexity of the role of
different chromosomal interactions and the dramatic
changes in transcriptional regulation that occur following
cohesin complex component depletion, a number of sec-
ondary effects such as those observed in our study may
occur. Furthermore, depletion of the cohesin complex will
likely result not only in the loss of chromosomal loops that
promote gene transcription (by bringing enhancers close
to genes), but also loops which repress gene transcription
(for example, cohesin binding sites which serve as insula-
tors). The net effect of cohesin depletion will be a complex
mixture of all of these effects.
One important aspect of these findings is their poten-
tial implication for the treatment of ERα-positive breast
cancer. We confirmed the findings of another study [35]
which clearly demonstrated that chronic bortezomib
treatment decreases both ESR1 mRNA and ERα protein
levels. Although the effects of proteasome inhibition are
highly pleiotropic, the finding that bortezomib treatment
leads to a rapid and parallel decrease in both SMC3 and
ESR1 gene expression opens an interesting new possible
mechanism for its potential utility in the treatment of
ERα-positive breast cancer. Although studies using bor-
tezomib as a single agent to treat breast cancer were
disappointing [37], new clinical studies are currently
underway in which bortezomib is being tested in com-
bination with a pure anti-estrogen specifically in ERα-
positive metastatic breast cancer (NCT01142401). Given
the results presented here, it would be particularly inter-
esting to investigate ERα expression in patients receiving
bortezomib treatment to determine if this effect is also
observed in vivo. Given the potential role of cohesin
downstream of the androgen receptor [21,22], combined
anti-androgen and bortezomib treatment may also prove
to be effective in combatting androgen-dependent pros-
tate cancer.
Analogous to the effects of bortezomib treatment, other
therapies may work by a similar epigenomic mechanism
to decrease ESR1 expression. For example, treatment of
MCF7 cells with several different histone deacetylase inhi-
bitors (HDACi) also resulted in decreased ESR1 expres-
sion and a concomitant decrease in estrogen-regulated
transcription [38]. Interestingly, although it is currently
unknown whether HDACi treatment affects SMC3 ex-
pression, the proteasomal subunit PSMB2 is downregu-
lated following HDAC inhibition [38]. Given the similar
effects observed between proteasome inhibition and pro-
teasome subunit knockdown [32], it is possible that the
effects of HDACi treatment on ESR1 expression may also
occur as a secondary effect through downregulation of
SMC3 expression. Future studies will need to address
whether the decrease in ERα levels following proteasome
or HDAC inhibition has a positive or negative effect on
tumorigenesis. While decreased ESR1 expression may ini-
tially decrease tumor growth, it is possible that these treat-
ments may, in fact, enhance the formation of more
aggressive ERα-negative tumors.
Finally, the finding that ESR1 expression is strongly
dependent upon the integrity of the cohesin complex may
also provide an insight into the molecular mechanisms be-
hind various developmental phenotypes observed in
CdLS. The question of whether NIPBL, SMC1A or SMC3
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mutation lead to decreased ERα levels in CdLS patients
will need to be further addressed. Similarly, whether pro-
teasome or HDAC inhibition lead to decreased ERα ex-
pression in patients, and how this leads to various side
effects (that is, related to fertility) should also be
investigated.
Conclusion
Based on the results presented here, we propose that the
ESR1 gene is an important transcriptional target of cohe-
sin and Mediator which is particularly sensitive to
changes in the integrity of these complexes. It also
uncovers a molecular mechanism and potential clinical
utility for various therapies which alter ESR1 expression
as a secondary effect following changes in SMC3 expres-
sion. Additional clinical studies, as well as cell culture
and mouse model studies, will help to determine the
clinical efficacy of these therapeutic strategies and their
efficacy in the treatment of breast cancer.
Methods
Cell culture and RNA interference
MCF7 cells were obtained from the Department of Tumor
Biology at the University Medical Center Hamburg-
Eppendorf (Hamburg, Germany) and were grown in phe-
nol red–free high-glucose DMEM (Invitrogen; Carlsbad,
California, USA) supplemented with 10% bovine growth
serum (Thermo Scientific; Waltham, MA, USA). MCF7 cells
were grown in DMEM containing 5% charcoal-dextran–
treated FBS (CSS; HyClone : Thermo Scientific, MA,
USA) 1 to 2 days prior to treatment with 10 nmol/L 17-β-
estradiol (Sigma-Aldrich; Missouri, USA) as indicated.
Where indicated, cells were treated with 50 nmol/L
bortezomib (LC Laboratories; Woburn, USA). Small inter-
fering RNAs for SMC3 (Dharmacon; Thermo Scientific,
USA; M-006834-01-0005), MED12 (Ambion; Invitrogen,
USA; a pool of s19362, s19363 and s19364), or a negative
control siRNA (Dharmacon; D-001206-13) were trans-
fected using Lipofectamine RNAiMAX (Invitrogen) accor-
ding to the manufacturer’s instructions. Flow cytometry
experiments were performed as previously described [39].
Antibodies and western blot
Antibodies for western blot and/or ChIP analyses were
beta-actin (Abcam; Cambridge, UK; ab6278), ERα (Santa
Cruz; CA, USA sc-543), non-specific IgG (Abcam;
ab46540), MED12 (Bethyl; TX, USA ; ICH-00180), RNA-
PII (sc-899), Ser2-phosphorylated RNAPII CTD [40],
and SMC3 (Abcam; ab9263). For Western blot analyses,
cells were lysed in RIPA buffer containing 1 mM Pefa-
bloc and 1 ng/μl aprotinin/leupeptin, separated by SDS-
PAGE and transferred to a nitrocellulose membrane.
Proteins were detected using the respective antibodies
by enhanced chemiluminescence.
Microarray and gene expression analysis
Total RNA was isolated from cells using the Qiazol re-
agent (Qiagen; Hilden, Germany) according to the manu-
facturer’s instructions. One microgram of total RNA was
reverse transcribed using random nonamers (Metabion;
Martinsried, Germany). Real-time PCR analysis was per-
formed as previously described [32] using the following
primers: CXCL12 [32] (forward: 50-TGCCAGAGCCAA
CGTCAAGCATC-30; reverse: 50-CGGGTCAATGCACAC
TTGTCTGTTGT-30), ESR1 (forward: 50-GCATTCTAC
AGGCCAAATTCA-30; reverse: 50-TCCTTGGCAGATTC
CATAGC-30), GREB1 [34] (forward: 50-GTGGTAGCCGA
GTGGACAAT-30; reverse: 50-ATTTGTTTCCAGCCCTC
CTT-30), 28S rRNA (forward: 50-CTTTAAATGGGTAA
GAAGCC-30 [32] ; reverse: 50-ATCAACCAACACCTTT
TCTG-30), MED12 (forward: 50-ACAGGCTCCCATGCT
GACGGA-30; reverse: 50-AAGGCAAGGTCCCCTCGG
GAG-30), PGR [32] (forward: 50-TCCACCCCGGTCGCT
GTAGG-30; reverse: 50-TAGAGCGGGCGGCTGGAAGT
-30), PKIB [32] (forward: 50-ACGTGGAGTCTGGGGTCG
CC-30; reverse: 50-GAGAGCCTCCAGTTTGAGGGGCA
-30), and SMC3 (forward: 50-GTTTCAACCCAGCTGG
CCCGTG-30; reverse: 50-CGATGGCTGACTTGGTCAC
CTTCCA-30). Gene expression was normalized to a con-
trol gene (28S rRNA) and expressed as fold induction rela-
tive to the untransfected, control condition. For whole
transcriptome analyses, microarray studies were per-
formed by the Vancouver Prostate Centre Laboratory for
Advanced Genome Analysis (Vancouver, Canada) using
the Illumina human HT-12 v4 beadchip. Gene expression
data were analyzed as previously described (Prenzel et al.,
2011). Heatmaps indicate genes which were at least 1.5-
fold up- or downregulated with P-values≤ 0.05. All gene
expression data has been deposited into the GEO reposi-
tory [accession number GSE38252].
Chromatin immunoprecipitation and chromosome
conformation capture assays
Chromatin immunoprecipitation was performed and
analyzed by quantitative real-time PCR as previously
described [32] using the following primers for various
positions along the ESR1 gene: TSS (forward: 50-AAG
TTGGAGGCCCGGGAGCC-30; reverse: 50-CCCGACG
GGAGCAAGTGCAG-30), cohesin binding site 1 (for-
ward: 50-CACGCTGGCTACATTTCAAGTGCTTCA-
30; reverse: 50-AGTGCTGCCATCTACAGGGTCGAC-
30), cohesin binding site 2 (forward: 50-AAACAGGCA
GCACGCAGTGTTTCT-30; reverse: 50-GTGATTGAG
CTCTTGTGGCTTCTTGGG-30), 30 end (forward: 50-
CCCCAGAGGCCGAGTGCCA-30; reverse: 50-CCTGC
CTGGAAAGGTGACATGTGTG-30). ChIP DNA sam-
ples were normalized to input DNA from the same
sample and expressed as percent input. Chromatin con-
formation capture studies were performed as described
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previously [32] using the following primer/probe com-
binations: CXCL12 positive interaction (forward:
50-GAAGGAAGAAGAAACATGGACTCTGCTCCA-30;
reverse: 50-ACAGAAGCTGGTTTACCGACTTGTCT
GT-30; internal probe: 50-Fam-GCCCCAGGGCACAA
CACACC-BHQ1-30), CXCL12 negative control (for-
ward: 50-GAAGGAAGAAGAAACATGGACTCTGCTC
CA-30; reverse: 50-CTCCCAGTGCAGAGGGAAGCAT
GT-30; internal probe: 50-Fam-GCCCCAGGGCACAA
CACACC-BHQ1-30), GREB1 positive interaction (for-
ward: 50-CTGGGCCTCTCCAGGGGGTTTT-30; re-
verse: 50- CCGCTGGTCAGCCGTTCAGG −30; internal
probe: 50-Fam-GTCAGGGCAAAGGACATGGCCAG-
BHQ1-30), GREB1 negative control (forward: 50-GC
CACTACATCCTTGGCTTTGTCCAC-30; reverse: 50-
CCGCTGGTCAGCCGTTCAGG-30; internal probe: 50-
Fam- GTCAGGGCAAAGGACATGGCCAG-BHQ1-30),




HQ1-3’). All interactions were quantified by real-time
PCR using standard curves containing digested and
re-ligated DNA from BAC clones (ImaGenes; Berlin,
Germany) covering the investigated regions of the CXCL12
(RP-13309I17) and GREB1 (RPCIB753E0150Q) genes
and normalized using a probe-primer pair detecting an
amplicon between BtgI sites as described previously [32].
Additional file
Additional file 1: Figure S1. RAD21 depletion significantly reduces the
estrogen-induced expression of ERα target genes. MCF7 cells transfected
with control or RAD21 siRNA were grown in normal growth medium for
24 h and then for another 42 h in hormone-depleted medium before
treating with 10 nM 17β-Estradiol (E2) for 6 h as indicated. Total mRNA
was extracted, reverse-transcribed and analyzed by quantitative real-time
PCR (qRT-PCR). (A) The expression levels of the estrogen-regulated genes
CXCL12, GREB1, PGR, and PKIB were normalized to 28S ribosomal mRNA,
graphed relative to the control sample and expressed as relative mRNA
expression; mean values + SD, n = 2. (B) Efficient knockdown of RAD21
and its effects on ESR1 mRNA levels was verified by qRT-PCR in the same
samples used in (A). RAD21 and ESR1 were normalized and expressed as
in (A). Mean values + SD, n = 2. Figure S2. SMC3 or MED12 knockdown
enhance hormone-withdrawal induced G1 cell cycle arrest. MCF7 cells
transfected with control, SMC3 or MED12 siRNA were grown in normal
growth medium for 24 h and then for another 42 h in hormone-
depleted medium before flow cytometric analyses. Shown are
representative profiles and the respective quantitation for duplicate
samples (± SD).
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